The CLL Global Research Foundation (CLLGRF) began as a concept from patients with chronic lymphocytic leukemia (CLL). The aim was to accelerate research in CLL; therefore the Foundation's goal is finding a cure for CLL as quickly as possible. The Foundation is built on a partnership between patients, their families, the research community and other investors in the cure of CLL. The keystones leading to a cure are: the development of new, effective, low toxicity treatments, initiatives leading to greater understanding of CLL biology and improved monitoring of disease activity and progress. Our research is patient oriented, and we preferentially fund projects whose findings translate into rapid clinical applications.
The role of the patients and their families in the Foundation is simple. They will invest in the future for themselves, their loved ones and other patients with CLL. The challenge to patients and families lies in both continual self-education about CLL and eliciting "outside the box" research from the medical community.
CLLGRF promotes a novel structure for research; our success relies heavily on the partnership between the scientific community and the beneficiaries of the research, namely patients and their families. The Foundation complements rather than replaces present funding mechanisms. Our funds serve to accelerate new ideas. The increased funding should allow for rapid transfer of laboratory results to clinical applications.
CLLGRF asks patients, scientists and other organizations to join us in a commitment to cure CLL as part of our goal of curing cancer, one disease at a time.
|
|
PRESIDENT'S CORNER
Opinions Reports from
Dr. Michael Keating
Dr. Michael Keating, professor of medicine at M. D. Anderson Cancer Center, serves as president and CEO of the CLL Global Research Foundation.
He is an internationally renowned CLL clinical scientist dedicated to patient care and to development of potentially curative CLL therapies. |
 |
Past Articles
|
|
